7 citations
,
November 2024 in “Chinese Medical Journal” Alopecia areata is a major ongoing health issue in China, especially affecting young people and females.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
7 citations
,
October 2024 in “Acta Dermato Venereologica” Higher inflammation markers are linked to more severe alopecia areata.
7 citations
,
August 2024 in “Clinical and Experimental Dermatology” Upadacitinib is effective and safe for treating severe alopecia areata in teens.
7 citations
,
July 2024 in “Dermatology Practical & Conceptual” SII is a useful and affordable tool to assess and monitor alopecia areata.
7 citations
,
July 2024 in “Frontiers in Immunology” COVID-19 can increase the risk of hair loss, especially in people over 40.
7 citations
,
April 2024 in “International Journal of Dermatology” Alopecia areata greatly affects the quality of life for children and their families.
7 citations
,
March 2024 in “Skin Research and Technology” miR-200c-3p could help diagnose and treat alopecia areata.
7 citations
,
November 2023 in “JAAD Case Reports” Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
7 citations
,
October 2023 in “Journal of Intelligent & Fuzzy Systems” The new model improves Alopecia Areata classification accuracy to 93.1%.
7 citations
,
September 2023 in “JAMA Dermatology” Most people with alopecia areata stop treatment within a year.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
7 citations
,
October 2022 in “Advances in Therapy” Current treatments for Alopecia Areata are unsatisfactory and need improvement.
7 citations
,
October 2022 in “Expert opinion on emerging drugs” New drugs for alopecia areata show promise but aren't universally effective, and hair loss often returns after stopping treatment.
7 citations
,
July 2022 in “Quality of Life Research” 80% scalp hair regrowth is a successful treatment for alopecia areata.
7 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Stress can trigger or worsen alopecia areata.
7 citations
,
February 2022 in “Journal of Cosmetic Dermatology” Injecting vitamin D3 into the skin is an effective treatment for patchy hair loss.
7 citations
,
February 2022 in “JAAD International” COVID-19 may be linked to hair loss or worsening of hair loss in some people.
7 citations
,
November 2021 in “JAAD Case Reports” Mogamulizumab can cause hair loss and skin rashes.
7 citations
,
July 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
7 citations
,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
7 citations
,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
7 citations
,
July 2020 in “Immunological Investigations” The rs231775 genetic variant is linked to a higher risk and severity of Alopecia Areata in males.
7 citations
,
February 2020 in “Clinical and Experimental Dermatology” Both HLA-B and MICA are independently linked to alopecia areata.
7 citations
,
July 2019 in “International journal of research in dermatology” Intralesional triamcinolone acetonide is more effective than platelet-rich plasma for treating scalp alopecia areata.
7 citations
,
June 2019 in “Cureus” Fractional lasers and microneedling, combined with topical agents, could potentially treat Alopecia Areata effectively, but more research is needed due to limited data.